Calls for papers
-
According to Lupin, the FDA has approved the company’s ANDA for a generic version of Par Pharmaceutical’s Nascobal single dose cyanocobalamin nasal spray. Lupin said that it will manufacture the nasal spray at its plant… Read more . . .
-
Krystal Biotech has announced the initiation of the Phase 1 CORAL-1/US dose escalation trial of its KB407 inhaled gene therapy for the treatment of cystic fibrosis. The Phase 1 study, which is being conducted at the… Read more . . .
-
MannKind Corporation has filed a notice with the US Securities and Exchange Commission (SEC) stating that manufacturing of clinical trial supplies for its planned Phase 2/3 study of MNKD-101 clofazimine inhalation suspension in patients with… Read more . . .
-
Liquidia Corporation will pay Pharmosa Biopharm $10 million up front plus development and sales milestones worth up to $215 million and royalties on potential sales for North American development and commercialization rights to Pharmosa’s L606 liposomal… Read more . . .
-
Orion Pharmaceuticals has announced plans for a €30 million expansion of its production facility in Espoo, Finland, including a new filling line for its Easyhaler dry powder inhalers. The company said that it is responding… Read more . . .
-
Verona Pharma announced that it has submitted an NDA to the FDA for the nebulized formulation of ensifentrine (RPL554), a PDE3/PDE4 inhibitor, for the treatment of COPD. The company said that the submission is supported… Read more . . .
-
According to TFF Pharmaceuticals, the company has received a 3-year Direct to Phase 2 Small Business Innovation Research (SBIR) grant worth ~$2.97 million from the National Institute of Allergy and Infectious Diseases (NIAID) for further… Read more . . .
-
US-based start-up Cystetic Medicines has announced the initiation of a Phase 1 SAD/MAD trial of its CM001 dry powder “molecular prosthetic” in healthy volunteers. The company is developing CM001 for the treatment of cystic fibrosis… Read more . . .
-
Tonix Pharmaceuticals announced that it will acquire the US rights to Tosymra sumatriptan nasal spray from Upsher-Smith along with Zembrace SymTouch sumatriptan injection, both for the treatment of migraines. Dr. Reddy’s subsidiary Promius Pharma submitted… Read more . . .
-
Virpax Pharmaceuticals said that it has signed a cooperative research and development agreement (CRADA) for evaluation of the company’s NobrXiol (VRP324) cannabidiol nasal powder in rodent models of epilepsy and seizures by the Epilepsy Therapy Screening… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland